Torsdag 6 Augusti | 12:31:13 Europe / Stockholm
Est. tid*
2027-02-16 07:30 Bokslutskommuniké 2026
2026-11-03 07:30 Kvartalsrapport 2026-Q3
2026-07-20 - Kvartalsrapport 2026-Q2
2026-05-07 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2026-05-06 - Årsstämma
2026-04-27 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-05 - Kvartalsrapport 2025-Q3
2025-09-22 - Extra Bolagsstämma 2025
2025-07-22 - Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2025-05-14 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-30 - Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2024-05-14 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-20 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2023-05-10 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-21 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-24 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning DVYSR 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Devyser Diagnostics utvecklar, tillverkar och säljer genetiska tester till laboratorier globalt. Produkterna används för DNA-tester inom onkologi, transplantation och ärftliga sjukdomar för att möjliggöra skräddarsydd cancerbehandling, diagnostik av ett stort antal genetiska sjukdomar och uppföljning av transplanterade patienter. Bolaget har sitt huvudkontor i Hägersten.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy

2026-08-06 08:00:00

Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian laboratory, marks an important step in expanding access to next-generation sequencing (NGS) by combining Illumina instrumentation with Devyser's assay portfolio.

The agreement includes the placement of an Illumina MiSeq™ i100 System under a reagent rental model. The customer will also utilize Devyser's Amplicon Suite software to support data analysis and reporting.

"Laboratories are increasingly looking for easy-to-implement NGS solutions," says Jan Wahlström, CEO of Devyser. "This agreement represents an important win for Devyser as the first commercial implementation under our reagent rental collaboration with Illumina. By combining Illumina's sequencing technology with Devyser's comprehensive assay portfolio and intuitive software, we can make advanced genetic analysis more accessible for laboratories looking to adopt or expand NGS without significant upfront capital investment."

The Italian laboratory will implement a range of Devyser's assays through the reagent rental offering, demonstrating the breadth of the company's portfolio. By replacing upfront capital investment with a predictable reagent purchasing commitment, the model lowers the barrier for laboratories to adopt advanced molecular analysis and modernize their workflows.

Italy continues to be one of Devyser's most important strategic markets, and this reagent rental agreement further strengthens the company's commercial presence while demonstrating the value of its collaboration with Illumina. The multi-year reagent commitment also underpins recurring, higher-visibility revenue for Devyser, and the agreement is expected to serve as a reference for additional reagent rental opportunities across Europe.